Skip to content
DataLookout
Menu

REDUCTIONNCT07917078

Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in the ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter (RVED/LVED) as measured by echocardiography
Timeframe: Between baseline and 48 hours

Secondary (12)

Change in the ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter (RVED/LVED) as measured by echocardiography
Clinical Deterioration
PE-Related Death
All cause Death
Recurrent PE
Show 7 moreShow less
Persistent Dyspnea
Functional outcome
Persistent Right Ventricular Dysfunction
Chronic thromboembolic pulmonary disease (CTEPD) and/or Chronic thromboembolic pulmonary hypertension (CTEPH)
Major bleeding
Clinically relevant non-major bleeding
Minor bleeding

Arms and interventions

Reduced-Dose Alteplase and Standard AnticoagulationActive comparator

Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) and reduced-dose alteplase \[25 mg continuous intravenous infusion for 2 hours\]

Standard AnticoagulationActive comparator

Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH)

Drugs: Alteplase, Standard Anticoagulation

Sites

26 sites in 1 country